Form 4: Arcus Biosciences CFO Granted Equity Awards

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, received grants of restricted stock units and stock options.

Summary

• Robert C. Goeltz II, Chief Financial Officer of Arcus Biosciences, Inc. (RCUS), was granted 24,000 restricted stock units (RSUs) and 96,000 stock options on January 23, 2026.
• The RSUs were granted at a price of $0 and will vest in four equal annual installments beginning December 15, 2026, contingent on continued service.
• The stock options have an exercise price of $22.13 and become exercisable in 48 equal monthly installments after January 1, 2026, also subject to continued service.
• Following these transactions, Mr. Goeltz beneficially owns 91,924 shares of common stock (including unvested RSUs) and 96,000 stock options.
• The stock options have an expiration date of January 22, 2036.

Sentiment

Score: 6

Explanation: The filing reports routine executive compensation, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests. There are no immediate negative implications, but also no significant positive news beyond standard practice.

Positives

• The grant of equity awards to the Chief Financial Officer aligns management's interests with those of shareholders, incentivizing long-term performance.
• The compensation structure, involving both RSUs and stock options with vesting schedules, encourages executive retention and sustained contribution to the company's success.

Negatives

• The grants represent dilution potential for existing shareholders as RSUs vest into common stock and options are exercised.

Risks

• The vesting of both RSUs and stock options is contingent on the reporting person's continued service to the company, meaning the awards could be forfeited if employment ceases before vesting.

Future Outlook

The equity awards are structured with future vesting dates, indicating an expectation of continued executive service and contribution to the company's long-term objectives.

Industry Context

Executive compensation through equity grants, such as restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries. This approach is commonly used to attract, retain, and motivate key personnel, aligning their financial incentives with the long-term success and shareholder value creation of the company.

Comparison to Industry Standards

• The use of both restricted stock units (RSUs) and stock options for executive compensation is a common practice across the biotech sector, similar to companies like Gilead Sciences or Amgen, which frequently utilize a mix of equity instruments to incentivize leadership.
• The vesting schedules (four equal annual installments for RSUs and 48 equal monthly installments for options) are typical for executive retention programs, designed to ensure long-term commitment, comparable to structures seen at peer companies in the development stage.
• The grant price of $0 for RSUs is standard, reflecting their nature as direct equity awards, while the option exercise price of $22.13, likely the market price on the grant date, is also a common practice for incentive stock options.

Stakeholder Impact

• Shareholders: The grants align the CFO's financial interests with shareholder value creation, but also represent potential future dilution.
• Employees: Standard executive compensation practices can positively influence overall employee morale and retention strategies by demonstrating a commitment to rewarding leadership.

Next Steps

• Robert C. Goeltz II must continue his service to Arcus Biosciences, Inc. for the restricted stock units and stock options to vest according to their respective schedules.

Key Dates

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Transaction, Executive Compensation, Restricted Stock Units, Stock Options, Equity Grant, Chief Financial Officer